BACKGROUND: Alterations in the circadian arterial pressure rhythm predict cardiovascular mortality. We examined the circadian arterial pressure rhythm and the effect of renin-angiotensin system blockade in congenic mRen2.Lewis hypertensive rats, a renin-dependent model of hypertension derived from the backcross of transgenic hypertensive [mRen-2]27 rats with Lewis normotensive ones. METHODS: Twenty-nine mRen2.Lewis hypertensive rats were randomly assigned to drink tap water (vehicle; n = 9), valsartan (30 mg/kg/day; n = 10), or valsartan (30 mg/kg/day) combined with aliskiren given subcutaneously (50 mg/kg/day; n = 10) for 2 weeks. Arterial pressure, heart rate, and locomotive activity were recorded with chronically implanted radiotelemetry probes. The awake/asleep ratio was calculated as [awake mean arterial pressure (MAP) mean - asleep MAP mean)] / (awake MAP mean) x 100. Plasma renin activity (PRA) and concentration (PRC), and plasma and kidney angiotensin II (Ang II) were measured by radioimmunoassay (RIAs). RESULTS: Untreated hypertensive rats showed an inverse arterial pressure rhythm, higher at day and lower at night, accompanied by normal rhythms of heart rate and locomotive activity. Treatment with valsartan or aliskiren and valsartan normalized the elevated arterial pressure and the arterial pressure rhythm, with the combination therapy being more effective in reducing MAP and in restoring the awake/asleep ratio. While PRA and PRC increased with the treatments, the addition of aliskiren to valsartan partially reversed the increases in plasma Ang II levels. Valsartan and the aliskiren and valsartan combination markedly reduced the renal cortical content of Ang II. CONCLUSION: The altered circadian arterial pressure rhythm in this renin-dependent hypertension model uncovers a significant role of Ang II in the desynchronization of the circadian rhythm of arterial pressure, heart rate, and locomotive activity.
BACKGROUND: Alterations in the circadian arterial pressure rhythm predict cardiovascular mortality. We examined the circadian arterial pressure rhythm and the effect of renin-angiotensin system blockade in congenic mRen2.Lewis hypertensiverats, a renin-dependent model of hypertension derived from the backcross of transgenic hypertensive [mRen-2]27 rats with Lewis normotensive ones. METHODS: Twenty-nine mRen2.Lewis hypertensiverats were randomly assigned to drink tapwater (vehicle; n = 9), valsartan (30 mg/kg/day; n = 10), or valsartan (30 mg/kg/day) combined with aliskiren given subcutaneously (50 mg/kg/day; n = 10) for 2 weeks. Arterial pressure, heart rate, and locomotive activity were recorded with chronically implanted radiotelemetry probes. The awake/asleep ratio was calculated as [awake mean arterial pressure (MAP) mean - asleep MAP mean)] / (awake MAP mean) x 100. Plasma renin activity (PRA) and concentration (PRC), and plasma and kidney angiotensin II (Ang II) were measured by radioimmunoassay (RIAs). RESULTS: Untreated hypertensiverats showed an inverse arterial pressure rhythm, higher at day and lower at night, accompanied by normal rhythms of heart rate and locomotive activity. Treatment with valsartan or aliskiren and valsartan normalized the elevated arterial pressure and the arterial pressure rhythm, with the combination therapy being more effective in reducing MAP and in restoring the awake/asleep ratio. While PRA and PRC increased with the treatments, the addition of aliskiren to valsartan partially reversed the increases in plasma Ang II levels. Valsartan and the aliskiren and valsartan combination markedly reduced the renal cortical content of Ang II. CONCLUSION: The altered circadian arterial pressure rhythm in this renin-dependent hypertension model uncovers a significant role of Ang II in the desynchronization of the circadian rhythm of arterial pressure, heart rate, and locomotive activity.
Authors: Jewell A Jessup; Patricia E Gallagher; David B Averill; K Bridget Brosnihan; E Ann Tallant; Mark C Chappell; Carlos M Ferrario Journal: Am J Physiol Heart Circ Physiol Date: 2006-06-09 Impact factor: 4.733
Authors: Timothy R Smith; Thomas Philipp; Bernard Vaisse; George L Bakris; Margaret Wernsing; Joseph Yen; Robert Glazer Journal: J Clin Hypertens (Greenwich) Date: 2007-05 Impact factor: 3.738
Authors: Norihito Moniwa; Jasmina Varagic; Sarfaraz Ahmad; Jessica L VonCannon; Stephen W Simington; Hao Wang; Leanne Groban; K Bridget Brosnihan; Sayaka Nagata; Johji Kato; Kazuo Kitamura; R Ariel Gomez; Maria L Sequeira Lopez; Carlos M Ferrario Journal: Hypertension Date: 2012-12-10 Impact factor: 10.190
Authors: Sarfaraz Ahmad; Jasmina Varagic; Jessica L VonCannon; Leanne Groban; James F Collawn; Louis J Dell'Italia; Carlos M Ferrario Journal: Biochem Biophys Res Commun Date: 2016-07-25 Impact factor: 3.575
Authors: Adam Whaley-Connell; Javad Habibi; Nathan Rehmer; Sivakumar Ardhanari; Melvin R Hayden; Lakshmi Pulakat; Caroline Krueger; Carlos M Ferrario; Vincent G DeMarco; James R Sowers Journal: Metabolism Date: 2013-01-24 Impact factor: 8.694
Authors: Norihito Moniwa; Jasmina Varagic; Stephen W Simington; Sarfaraz Ahmad; Sayaka Nagata; Jessica L Voncannon; Carlos M Ferrario Journal: Am J Physiol Heart Circ Physiol Date: 2013-06-28 Impact factor: 4.733